<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="143096">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02128984</url>
  </required_header>
  <id_info>
    <org_study_id>VIT-2572-011</org_study_id>
    <nct_id>NCT02128984</nct_id>
  </id_info>
  <brief_title>Clinical Study With an Enteral Formula With Symbiotic and DHA for Malnourished Children</brief_title>
  <acronym>VITJUNIOR</acronym>
  <official_title>Clinical Study With an Enteral Formula With Symbiotic and DHA for Malnourished Children</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Laboratorios Ordesa</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Quantum Experimental</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Peruvian Clinical Research</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Laboratorios Ordesa</source>
  <oversight_info>
    <authority>Spain: Ethics Committee</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether a nutritional supplement is effective in
      the treatment of malnutrition in pediatric patients with failure to thrive or cystic
      fibrosis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a multicenter, controlled, randomized, prospective, parallel-group, double-blind
      study to evaluate the effect of a nutritional supplement on nutritional status in children
      with failure to thrive or cystic fibrosis. Patients will be randomized to receive either a
      symbiotic formula with DHA and antioxidants or a standard formula.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2012</start_date>
  <completion_date type="Anticipated">June 2015</completion_date>
  <primary_completion_date type="Anticipated">December 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Changes in inflammatory response</measure>
    <time_frame>At 3rd and 6th months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Differences in faecal calprotectin's levels after 3rd and 6th months of treatment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in nutritional status</measure>
    <time_frame>At 3rd and 6th months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Differences measured by changes in weight, height, growth Z-scores, fat body mass and lean body mass.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in microbiota profile</measure>
    <time_frame>At 3rd and 6th months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Differences measured by changes in faecal microbiota composition.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Interleukin levels</measure>
    <time_frame>At 6th month</time_frame>
    <safety_issue>No</safety_issue>
    <description>Differences in faecal interleukin levels. Only for cystic fibrosis patients.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Infections</measure>
    <time_frame>At 1st, 3rd and 6th months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Episodes of infections during the study period</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Tolerability</measure>
    <time_frame>At 1st, 3rd and 6th months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Tolerability to the formula in both groups</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">130</enrollment>
  <condition>Cystic Fibrosis</condition>
  <condition>Failure to Thrive</condition>
  <condition>Malnutrition</condition>
  <arm_group>
    <arm_group_label>Vitafos Junior</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Symbiotic Formula with DHA and antioxidants</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard Formula</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Standard isocaloric and isonitrogenous formula.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Symbiotic Formula with DHA and antioxidants</intervention_name>
    <description>6 months intervention.</description>
    <arm_group_label>Vitafos Junior</arm_group_label>
    <other_name>Vitafos Junior</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Standard Formula</intervention_name>
    <description>6 months intervention.</description>
    <arm_group_label>Standard Formula</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Malnutrition (P / T &lt;-1 SD) by intake deficit without organic disease (failure to
             thrive) and / or patients diagnosed with Cystic Fibrosis).

          -  Age &gt;= 1 year.

          -  Stable patients

          -  No antibiotherapy in the last 30 days

          -  Inform consent signed (parent/legal representative)

        Exclusion Criteria:

          -  Patients with allergy / intolerance to cow's milk proteins

          -  Metabolically unstable patient

          -  Patients with metabolic intolerance to carbohydrates

          -  Patients with severe disease in the last 30 days
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Rosa Lama, Doctor</last_name>
    <phone>678607358</phone>
    <email>maquedalama@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Instituto Nacional de Salud del Niño</name>
      <address>
        <city>Lima</city>
        <state>Breña</state>
        <country>Peru</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Juan Rivera Medina, Doctor</last_name>
      <phone>00051 994615917</phone>
      <email>juan.riveramedina@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Juan Rivera Medina, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital de Henares</name>
      <address>
        <city>Coslada</city>
        <state>Madrid</state>
        <zip>28822</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Santa Lucía</name>
      <address>
        <city>Cartagena</city>
        <state>Murcia</state>
        <zip>30202</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Hospital de Torrecárdenas</name>
      <address>
        <city>Almería</city>
        <zip>04009</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Puerta del Mar</name>
      <address>
        <city>Cádiz</city>
        <zip>11009</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario La Paz</name>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Virgen Macarena</name>
      <address>
        <city>Sevilla</city>
        <zip>41009</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Miguel Servet</name>
      <address>
        <city>Zaragoza</city>
        <zip>50009</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location_countries>
    <country>Peru</country>
    <country>Spain</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>April 30, 2014</lastchanged_date>
  <firstreceived_date>March 28, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Malnutrition</keyword>
  <keyword>Dietary supplement</keyword>
  <keyword>Nutritional supplement</keyword>
  <keyword>Symbiotic formula</keyword>
  <keyword>DHA</keyword>
  <keyword>Cystic Fibrosis</keyword>
  <keyword>Failure to Thrive</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Cystic Fibrosis</mesh_term>
    <mesh_term>Failure to Thrive</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
    <mesh_term>Malnutrition</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Antioxidants</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
